Professor Ben van Hout

Population Health, School of Medicine and Population Health

Emeritus Professor of Health Economics

b.a.vanhout@sheffield.ac.uk
+44 114 222 0827

+44 114 222 0749 (Fax)

Regent Court (ScHARR)

Full contact details

Professor Ben van Hout
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA

Profile

I joined ScHARR in November 2009 as Professor of Health Economics.

I have extensive experience in modelling and have contributed to the methodology of economic evaluation in various areas. In 1993 I was one of the earliest researchers to apply discrete event models and was the first to apply a non-parametric method to estimate costs in the presence of censoring. In 1994 I was the first to apply Fieller's approach to calculate confidence intervals around cost-effectiveness ratios, and I introduced the acceptability curve, which is now a well-known concept in cost-effectiveness analysis. In 1996 I was one of the first to apply probabilistic sensitivity analysis. In 2000 I was one of the initial people to explore Bayesian techniques in economic evaluation. I have had work published on discounting and estimating utility functions.

I am one of the founding members of the EuroQol group and I currently enjoy chairing the valuation task force within the EQ-5D group. My experience covers several therapeutic areas, including renal disease, cancer, osteoporosis, sepsis, schizophrenia, blood safety and most notably cardiovascular disease. My main interest concerns the use of elegant techniques, mostly to solve practical problems, but sometimes also because of the elegance itself.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO
Begum N, Stephens S, Schoeman O, Fraschke A, Kirsch B, Briere J-B, Verheugt FWA & van Hout BA (2015) Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4(2), 131-153. View this article in WRRO
Stephens S, Botteman MF, Cifaldi MA & van Hout BA (2015) Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open, 5(6). View this article in WRRO
Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2015) The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 18(4), 376-386.
Rowen D, Brazier J & Van Hout B (2015) A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
Golicki D, Niewada M, Hout BV, Janssen MF & Pickard AS (2014) Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Value in Health Regional Issues, 4, 19-23.
Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2014) Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), 935-943. View this article in WRRO
Ara R, Kearns B, vanHout BA & Brazier JE (2014) Predicting preference-based utility values using partial proportional odds models.. BMC Res Notes, 7, 438. View this article in WRRO
Heeg BM & van Hout BA (2014) Assessing uncertainties surrounding combined endpoints for use in economic models.. Med Decis Making, 34(3), 300-310.
Mulhern B, Devlin N, Shah K, Feng Y & Van Hout B (2013) Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.

All publications

Journal articles

Puelles J, Arija P, Durno N, Pantiri K, Subramanian R, Jack K, Chambenoit O, Boeri M, van Hout B & Silverberg JI (2024) 691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment. British Journal of Dermatology, 191(Supplement_2).
Schneider P, Devlin N, van Hout B & Brazier J (2024) Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level. Health Economics. View this article in WRRO
Schneider P, Blankart K, Brazier J, van Hout B & Devlin N (2024) Using the Online Elicitation of Personal Utility Functions Approach to Derive a Patient-Based 5-Level Version of EQ-5D Value Set: A Study in 122 Patients With Rheumatic Diseases From Germany. Value in Health, 27(3), 376-382.
Devlin NJ, Pan T, Sculpher M, Jit M, Stolk E, Rowen D, van Hout B & Norman R (2023) Using age-specific values for pediatric HRQoL in cost-effectiveness analysis: is there a problem to be solved? If so, how?. PharmacoEconomics, 41(10), 1165-1174. View this article in WRRO
Powell PA, Karimi M, Rowen D, Devlin N, van Hout B & Brazier JE (2023) Hypothetical versus experienced health state valuation: a qualitative study of adult general public views and preferences. Quality of Life Research, 32(4), 1187-1197.
Schneider P, van Hout B, Heisen M, Brazier J & Devlin N (2022) The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states [version 1; peer review: 1 approved]. Wellcome Open Research, 7. View this article in WRRO
Piena MA, Kroep S, Simons C, Fenwick E, Harty GT, Wong SL & van Hout BA (2022) An innovative approach to modelling the optimal treatment sequence for patients with relapsing–remitting multiple sclerosis : implementation, validation, and impact of the decision-making approach. Advances in Therapy, 39(2), 892-908. View this article in WRRO
Landmesser U, Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Svensson ME, Sibartie M & Fonarow GC (2022) Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes, 8(1), 31-38.
van Hout BA & Shaw JW (2021) Mapping EQ-5D-3L to EQ-5D-5L. Value in Health, 24(9), 1285-1293.
Bunge EM, van Hout B, Haas S, Spentzouris G & Cohen A (2021) Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review. BMJ Open, 11(2). View this article in WRRO
Morrone D, Kroep S, Ricci F, Renda G, Patti G, Kirchhof P, Chuang L-H, van Hout B & De Caterina R (2020) Mortality prediction of the CHA2DS2-VASc score, the HAS-BLED score, and their combination in anticoagulated patients with atrial fibrillation. Journal of Clinical Medicine, 9(12).
Descamps OS, Van Hout B, Lindgren P, Villa G, Urbich M & Fonarow GC (2020) Cost-effectiveness of evolocumab in patients with familial hypercholesterolemia in Belgium. Atherosclerosis, 315, e36-e36.
Ray KK, Bridges I, Bruckert E, Van Hout B, Sibartie M & Villa G (2020) What potential risk reduction could be achieved with evolocumab treatment? A simulation based on observational data from a cohort of users in 10 European countries. European Heart Journal, 41(Supplement_2).
Ray KK, Bruckert E, Van Hout B, Feudjo Tepie M, Bridges I & Sibartie M (2020) Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study. European Heart Journal, 41(Supplement_2).
Morrone D, Kroep S, Ricci F, Renda G, Patti G, Kirchhof P, Chuang LC, Van Hout B & De Caterina R (2020) Additive predictive power of the CHA2DS2-VASc and HAS-BLED scores for mortality in patients with atrial fibrillation. European Heart Journal, 41(Supplement_2).
van Hout B, Hawe E & Cohen AT (2020) Impact of patient characteristics on treatment outcomes in symptomatic venous thromboembolism: Results of HOKUSAI-VTE randomized trial analysis. TH Open, 04(03), e245-e254.
van Hout B, Mulhern B, Feng Y, Shah K & Devlin N (2020) The EQ-5D-5L value set for England : response to the “Quality Assurance”. Value in Health. View this article in WRRO
Bouwmeester W, Briggs A, van Hout B, Hájek R, Gonzalez-McQuire S, Campioni M, DeCosta L & Brozova L (2019) Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting. Oncology and Therapy, 7(2), 141-157. View this article in WRRO
Fonarow GC, van Hout B, Villa G, Arellano J & Lindgren P (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology. View this article in WRRO
Chuang L-H, Gumbs P, van Hout B, Agnelli G, Kroep S, Monreal M, Bauersachs R, Willich SN, Gitt A, Mismetti P , Cohen A et al (2019) Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries.. Quality of Life Research. View this article in WRRO
Chuang L-H, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Gitt AK, Monreal M, Willich SN & van Hout B (2019) Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 28(5), 1155-1177.
Stolk E, Ludwig K, Rand K, van Hout B & Ramos-Goñi JM (2019) Overview, update, and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol. Value in Health, 22(1), 23-30. View this article in WRRO
Willich SN, Chuang L-H, van Hout B, Gumbs P, Jimenez D, Kroep S, Bauersachs R, Monreal M, Agnelli G & Cohen A (2018) Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 170, 181-191. View this article in WRRO
Chuang LH, van Hout B, Cohen AT, Gumbs PD, Kroep S, Bauersachs R, Gitt A, Monreal M, Willich SN & Agnelli G (2018) Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 170, 165-174. View this article in WRRO
Devlin NJ, Shah KK, Mulhern BJ, Pantiri K & van Hout B (2018) A new method for valuing health: directly eliciting personal utility functions. The European Journal of Health Economics. View this article in WRRO
Feng Y, Hole A, Karimi M, Tsuchiya A & van Hout BA (2018) An exploration of the non‐iterative time trade‐off method to value health states. Health Economics, 27(8), 1247-1263. View this article in WRRO
Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B & Devlin N (2018) Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics, 36(6), 727-727.
Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B & Devlin N (2018) Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics, 1-15. View this article in WRRO
Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2018) Valuing health‐related quality of life: An EQ‐5D‐5L value set for England. Health Economics, 27(1), 7-22. View this article in WRRO
Clay E, Jamotte A, Verhamme P, Cohen AT, Van Hout BA & Gumbs P (2018) Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 6(1), 1495974-1495974. View this article in WRRO
Feng Y, Devlin N, Shah KK, Mulhern B & van hout B (2018) New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics, 27(1), 23-38. View this article in WRRO
Rowen DL, Azzabi Zouraq I, Chevrou-Severac H & van Hout B (2017) INTERNATIONAL REGULATIONS AND RECOMMENDATIONS FOR UTILITY DATA FOR HEALTH TECHNOLOGY ASSESSMENT. PharmacoEconomics, 35(Suppl 1), 11-19. View this article in WRRO
Ara RM, Peasgood T, Mukuria C, Chevrou-Severac H, Rowen D, Azzabi-Zouraq I, Paisley S, van Hout B & Brazier J (2017) Sourcing and using appropriate health state utility values in economic models in health care. PharmacoEconomics, 35(Suppl 1), 7-9. View this article in WRRO
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R & Sabatine MS (2017) Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiology. View this article in WRRO
Waldeck AR, Botteman MF, White RE & van Hout BA (2017) The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making. Journal of Managed Care & Specialty Pharmacy, 23(6-a Suppl), S6-S12. View this article in WRRO
Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A & Hout BV (2017) Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39(4), 771-786.e3. View this article in WRRO
Bennison C, Stephens S, Lescrauwaet B, Van Hout B & Jackson TL (2016) Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole. Journal of Market Access & Health Policy, 4(1). View this article in WRRO
Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO
Begum N, Stephens S, Schoeman O, Fraschke A, Kirsch B, Briere J-B, Verheugt FWA & van Hout BA (2015) Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4(2), 131-153. View this article in WRRO
Taylor B, Lothgren M, Villa G, Lindgren P, Van Hout B & Mark D (2015) Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom. Circulation, 132(suppl_3).
Stephens S, Botteman MF, Cifaldi MA & van Hout BA (2015) Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open, 5(6). View this article in WRRO
Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2015) The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 18(4), 376-386.
Rowen D, Brazier J & Van Hout B (2015) A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
Golicki D, Niewada M, Hout BV, Janssen MF & Pickard AS (2014) Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Value in Health Regional Issues, 4, 19-23.
Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2014) Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), 935-943. View this article in WRRO
Ara R, Kearns B, vanHout BA & Brazier JE (2014) Predicting preference-based utility values using partial proportional odds models.. BMC Res Notes, 7, 438. View this article in WRRO
Oppe M, Devlin NJ, van Hout B, Krabbe PFM & de Charro F (2014) A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.. Value Health, 17(4), 445-453.
Heeg BM & van Hout BA (2014) Assessing uncertainties surrounding combined endpoints for use in economic models.. Med Decis Making, 34(3), 300-310.
Gu NY, Botteman MF, Gerber RA, Ji X, Postema R, Wan Y, Sianos G, Anthony I, Cappelleri JC, Szczypa P & van Hout B (2013) Eliciting health state utilities for Dupuytren's contracture using a discrete choice experiment.. Acta Orthop, 84(6), 571-578. View this article in WRRO
Majer IM, Gueron B, Kotapati S & Van Hout B (2013) Extrapolating Survival in a Heterogeneous Patient Population with Metastatic Melanoma; A Case Study of Integrating Statistical and Clinical Consideration. Value in Health, 16(7), A594-A594.
Thurston S & Van Hout B (2013) Disentangling Effects on Fatal and Non-Fatal Cardiovascular Events Over Time. Value in Health, 16(7), A590-A590.
Mulhern B, Devlin N, Shah K, Feng Y & Van Hout B (2013) Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.
Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G & Van Hout B (2013) A comparison of alternative variants of the lead and lag time TTO. Health Economics (United Kingdom), 22(5), 517-532.
Krabbe PFM, Devlin N, Stolk E, Shah K, Oppe M, Van Hout B, Pickard S & Xie F (2012) Evidence from four countries on the validity of the discrete choice model in quantifying health-states for the new EQ-5D-5L. QUALITY OF LIFE RESEARCH, 21, 12-12.
Gu NY, Bell C, Botteman MF, Ji X, Carter JA & van Hout B (2012) Estimating Preference-Based EQ-5D Health State Utilities or Item Responses from Neuropathic Pain Scores. The Patient: Patient-Centered Outcomes Research, 5(3), 185-197.
Gu NY, Bell C, Botteman MF, Ji X, Carter JA & van Hout B (2012) Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores.. Patient, 5(3), 185-197.
van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P & Pickard AS (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.. Value Health, 15(5), 708-715.
Gu NY, Botteman M, Gerber R, Ji X, Postema R, Wan W, Sianos G, Anthony I, Cappelleri JC, Szczypa P & Van Hout B (2012) PMS91 Using Discrete Choice Experiments (DCE) to Estimate Preference-Based Utilities for Dupuytren's Contracture (DC). Value in Health, 15(4), A50-A50.
Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, Den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S , Leadley K et al (2012) Quality of Life After PCI With Drug-Eluting Stents in Coronary Artery Bypass Surgery. Survey of Anesthesiology, 56(1), 6-6.
Rowen D, Mulhern B, Banerjee S, Van Hout B, Young TA, Knapp M, Smith SC, Lamping DL & Brazier JE (2012) Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-proxy. Value in Health, 15(2), 346-356.
Borkent-Raven BA, Janssen MP, Van Der Poel CL, Bonsel GJ & Van Hout BA (2012) Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion, 52(3), 478-488.
Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ & van Hout BA (2012) Cost-effectiveness of additional blood screening tests in the Netherlands.. Transfusion, 52(3), 478-488.
Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, Pinto D, Magnuson EA, Mcgarry TF, Lucas SK , Horwitz PA et al (2012) Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial.. Catheter Cardiovasc Interv, 79(2), 198-209.
Gu NY, Botteman MF, Ji X, Bell CF, Carter JA & van Hout B (2011) Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities.. Health Qual Life Outcomes, 9, 119. View this article in WRRO
Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Heijer P, Vrakking MM, Wang K, Mahoney EM, Audi S , Leadley K et al (2011) Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery.. N Engl J Med, 364(11), 1016-1026.
Raaijmakers MA, Posthumus JA, van Hout BA, van Engeland H & Matthys W (2011) Cross-sectional study into the costs and impact on family functioning of 4-year-old children with aggressive behavior.. Prev Sci, 12(2), 192-200. View this article in WRRO
Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM & van Hout BA (2011) A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.. Haematologica, 96(5), 738-743.
Van Hout BA (2011) Safe blood transfusion: How much do we want to pay?. Blood Transfusion, 9(SUPPL. 1).
Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2011) Survival after transfusion in the Netherlands.. Vox Sang, 100(2), 196-203.
Gu NY, Bell C, Ji X, Carter J, Botteman M & Van Hout BA (2010) PSY67 PREDICTING EQ-5D UTILITIES FROM NEUROPATHIC PAIN SCORES: COMPARING INDIRECT MAPPING OF PREDICTED ITEM RESPONSES WITH DIRECT MAPPING OF SCORES. Value in Health, 13(7), A472-A473.
Wassenberg MWM, de Wit GA, van Hout BA & Bonten MJM (2010) Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA.. PLoS One, 5(7), e11562. View this article in WRRO
Logman J, Heeg B, Herlitz J & Hout B (2010) Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden. Applied Health Economics and Health Policy, 8(4), 251-265.
Logman JFS, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A & van Hout BA (2010) Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.. Curr Med Res Opin, 26(7), 1565-1578.
Thurston SJ, Heeg B, de Charro F & van Hout B (2010) Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.. Curr Med Res Opin, 26(3), 641-651.
Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2010) The PROTON study: profiles of blood product transfusion recipients in the Netherlands.. Vox Sang, 99(1), 54-64.
Morice M-C, Hout BV, Berland J, Bessou J-P, Carrié D, Dawkins K, Mohr F & Serruys P (2010) 059 Economic evaluation of the French subset of the SYNTAX trial at 1 year: drug-eluting stents compared with bypass surgery for patients with 3-vessel and/or left main coronary artery disease. Archives of Cardiovascular Diseases Supplements, 2(1), 20-20.
Hensen M, Heeg B, Löthgren M & van Hout B (2010) Cost effectiveness of long-acting risperidone in Sweden.. Appl Health Econ Health Policy, 8(5), 327-341.
Logman JFS, Heeg BMS, Herlitz J & van Hout BA (2010) Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.. Appl Health Econ Health Policy, 8(4), 251-265.
Logman JFS, Heeg BMS, Botteman MF, Kaura S & van Hout BA (2010) Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.. Ann Oncol, 21(7), 1529-1536.
Logman F, Heeg B, Botteman M, Kaura S & van Hout B (2009) Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom.. Poster Session Abstracts.
Lieuw On MML, Heeg BMS, De Charro F & van Hout BA (2009) MO12 COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. Value in Health, 12(7), A235-A235.
Janssen MP, Cator EA, van der Poel CL, Schaasberg WP, Bonsel GJ & van Hout BA (2009) Monitoring viral incidence rates: tools for the implementation of European Union regulations.. Vox Sang, 96(4), 298-308.
Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F & Van Hout B (2009) Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.. Haemophilia, 15(2), 420-436.
Treur M, Heeg B, Möller H-J, Schmeding A & van Hout B (2009) A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.. BMC Health Serv Res, 9, 32. View this article in WRRO
Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ & van Hout BA (2009) Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.. Transfusion, 49(2), 311-319.
Turpie AG, Kreutz R, Haas S & Van Hout B (2009) Clinical benefits of rivaroxaban for VTE prevention after elective hip or knee replacement surgery. EJHP Practice, 15(3), 34-36.
Logman JFS, Heeg BMS, Botteman MF, Kaura S & van Hout BA (2008) Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in post-menopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom. European Journal of Cancer Supplements, 6(7), 69-70.
Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F & van Hout B (2008) The cost-effectiveness of atypicals in the UK.. Value Health, 11(7), 1007-1021.
Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens JM, Haider S, Cappelleri JC, Nathwani D, Tice A & Van Hout BA (2008) PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI):A BAYESIAN META-ANALYSIS. Value in Health, 11(6), A428-A428.
Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. EuroIntervention, 4(2), 193-199.
Vahanian A, Alfieri OR, Al-Attar N, Antunes MJ, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. Eur J Cardiothorac Surg, 34(1), 1-8.
Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournial G, Kappetein AP , Kovac J et al (2008) Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI).. Eur Heart J, 29(11), 1463-1470.
Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML & Guideline development group for the Dutch guideline for multidisciplinary cardiovascular risk management (2008) Clinical practice guideline for cardiovascular risk management in the Netherlands.. Neth J Med, 66(4), 169-174.
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, Van HBA , Willian AR et al (2008) Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group (vol 14, pg 127, 2008). HAEMOPHILIA, 14(2), 414-414.
Raaijmakers M, Koffijberg H, Posthumus J, van Hout B, van Engeland H & Matthys W (2008) Assessing performance of a randomized versus a non-randomized study design.. Contemp Clin Trials, 29(2), 293-303.
Hensen M, Treur MJ, Heeg BMS, Lothgren M & Van Hout B (2008) 98 – Health-economic analysis of risperidone long-acting injectable compared to olanzapine and a conventional depot in Sweden and Finland. Schizophrenia Research, 98, 73-74.
Heeg BMS, Antunes J, Figueira ML, Jara JM, Marques Teixeira J, Palha AP, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C & Van Hout BA (2008) Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.. Curr Med Res Opin, 24(2), 349-358.
Heeg BMS, Damen J, Buskens E, Caleo S, de Charro F & van Hout BA (2008) Modelling approaches: the case of schizophrenia.. Pharmacoeconomics, 26(8), 633-648.
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Schramm W, van Hout BA , Willan AR et al (2008) Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.. Haemophilia, 14(1), 127-132.
Janssen MP, Over J, van der Poel CL, Cuijpers HTM & van Hout BA (2008) A probabilistic model for analyzing viral risks of plasma-derived medicinal products.. Transfusion, 48(1), 153-162.
Heeg B, Damen J & Hout B (2007) Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events. PharmacoEconomics, 25(12), 1063-1082.
Treur MJ, McCracken F, Heeg B, Joshi AV, Thurston S, Verheggen B, Marc B, de Charro F & van Hout B (2007) Efficacy of Recombinant Activated Factor VII (rFVIIa) vs. Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia with Inhibitors: A Bayesian Meta-Analysis.. Blood, 110(11), 3964-3964.
Logman JFS, Taylor MJ, Neumann K, Kutikova L, Cerri KH, Van Hout BA & Kühr T (2007) PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA. Value in Health, 10(6), A325-A325.
Damen J, Heeg B, Lothgren M & Van Hout BA (2007) PMH24 THE COST EFFECTIVENESS OF PALIPERIDONE EXTENDED-RELEASE OROS IN SWEDEN, FINLAND, DENMARK AND NORWAY. Value in Health, 10(6), A294-A295.
Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) PMH22 A PHARMACOECONOMIC ANALYSIS OF COMPLIANCE GAINS ON ANTIPSYCHOTIC MEDICATIONS. Value in Health, 10(6), A294-A294.
Opstelten W, van Wijck AJ, van Essen GA, Moons KG, Verheij TJ, Kalkman CJ & van Hout BA (2007) Cost effectiveness of epidural injection of steroids and local anesthetics for relief of zoster-associated pain.. Anesthesiology, 107(4), 678-679.
Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL & van Hout BA (2007) Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.. Rheumatology (Oxford), 46(8), 1320-1328.
Heeg B, Damen J & Van Hout B (2007) Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.. Pharmacoeconomics, 25(12), 1063-1082.
Heeg BMS, Peters RJG, Botteman M & van Hout BA (2007) Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.. Pharmacoeconomics, 25(9), 769-782.
Ong ATL, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT & Serruys PW (2006) Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.. Eur Heart J, 27(24), 2996-3003.
Heeg B, van Gestel A, Hout BV, Olsen J & Haghfelt TH (2006) [Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].. Ugeskr Laeger, 168(35), 2911-2915.
Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ & van Hout BA (2006) Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.. Transfusion, 46(6), 956-965.
Buskens E, Meijboom MJ, Kooijman H & Van Hout BA (2006) The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysis.. J Cardiovasc Surg (Torino), 47(2), 161-170.
Heeg B, Van Gestel A, Van Hout B, Olsen J & Haghfelt TH (2006) Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark. Ugeskrift for Laeger, 168(35), 2911-2915.
Van Hout B & Pharmerit BV (2005) PCV90 COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS. Value in Health, 8(6), A116-A116.
Van Hout B & Pharmerit BV (2005) PCV91 COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS. Value in Health, 8(6), A116-A116.
Moller HJ, Laux G, Naber D, Gastpar MT, Klosterkotter J, Schmauss M, Heeg B, Van Gestel A, Van Hout B & Mehnert A (2005) Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. PSYCHOPHARMAKOTHERAP, 12(5), 183-192.
Al MJ, Feenstra TL & van Hout BA (2005) Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. HEALTH ECON, 14(7), 655-667.
van Hout BA, Serruys PW, Lemos PA, van den Brand MJBM, van Es G-A, Lindeboom WK & Morice M-C (2005) One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial.. Heart, 91(4), 507-512.
Hak E, Buskens E, van Essen GA, de Bakker DH, Grobbee DE, Tacken MAJB, van Hout BA & Verheij TJM (2005) Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study.. Arch Intern Med, 165(3), 274-280.
Möller HJ, Laux G, Naber D, Gastpar MT, Klosterkötter J, Schmauss M, Heeg B, Van Gestel A, Van Hout B & Mehnert A (2005) Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany. Psychopharmakotherapie, 12(5), 183-192.
Laux G, Heeg B, van Hout BA & Mehnert A (2005) Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.. Pharmacoeconomics, 23 Suppl 1, 49-61.
Chue PS, Heeg B, Buskens E & van Hout BA (2005) Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.. Pharmacoeconomics, 23 Suppl 1, 62-74.
Heeg B, Buskens E, Knapp M, van Aalst G, Dries PJT, de Haan L & van Hout BA (2005) Modelling the treated course of schizophrenia: development of a discrete event simulation model.. Pharmacoeconomics, 23 Suppl 1, 17-33.
Clermont G, Kaplan V, Moreno R, Vincent JL, Linde-Zwirble WT, Van Hout B & Angus DC (2004) Dynamic microsimulation to model multiple outcomes in cohorts of critically ill patients. INTENS CARE MED, 30(12), 2237-2244.
Serruys PW, Lemos PA, van Hout BA & Arterial Revascularisation Therapies Study part II Steering Committee and Investigators (2004) Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).. Heart, 90(9), 995-998.
van Gestel A, Bakker J, Veraart CPWM & van Hout BA (2004) Prevalence and incidence of severe sepsis in Dutch intensive care units.. Crit Care, 8(4), R153-R162. View this article in WRRO
Bakker J, Levi M, van Hout BA & van Gestel A (2004) [Sepsis, a complicated syndrome with major medical and social consequences].. Ned Tijdschr Geneeskd, 148(20), 975-978.
Legrand VMG, Serruys PW, Unger F, van Hout BA, Vrolix MCM, Fransen GMP, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JMG , Neves JPMDS et al (2004) Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease.. Circulation, 109(9), 1114-1120.
Bakker J, Levi M, Van Hout BA & Van Gestel A (2004) Sepsis, a complicated syndrome with major medical and social consequences. Nederlands Tijdschrift voor Geneeskunde, 148(20), 975-978.
Heeg BM, Emmermann A, Laux G, Möller HJ, Naber D & Van Hout BA (2003) PMH10 COSTS AND EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY. Value in Health, 6(6), 691-692.
van Hout BA, Minjoulat-Rey MC, Quinlan D, Theeuwes A & Gabriel S (2003) Cost-effectiveness of extending prophylaxis with fondaparinux in preventing venous thromboembolism following hip fracture surgery. VALUE HEALTH, 6(6), 652-652.
van Hout BA, Tangelder MJD, Bervoets P & Gabriel S (2003) Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke, and peripheral arterial disease in the Netherlands. VALUE HEALTH, 6(6), 653-653.
Maliwa MA, van der Heijden GJMG, Bots ML, van Hout BA, Casselman FP, van Swieten H & Vermeulen FEE (2003) Quality of life and NYHA class 30 years after mechanical aortic valve replacement.. Cardiovasc Surg, 11(5), 381-387.
Van Hout B, Gagnon D & Guastalla J-P (2003) 1052 Cost-effectiveness of epoetin alfa (EPO) and darbepoetin alfa (DARB) based on hematopoietic response rates and cost of therapy. European Journal of Cancer Supplements, 1(5), S313-S314.
Klok RM, Postma MJ, van Hout BA & Brouwers JRBJ (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use.. Aliment Pharmacol Ther, 17(10), 1237-1245.
Hak E, van Loon S, Buskens E, van Essen GA, de Bakker D, Tacken MAJB, van Hout BA, Grobbee DE & Verheij TJM (2003) Design of the Dutch prevention of influenza, surveillance and management (PRISMA) study.. Vaccine, 21(15), 1719-1724.
van Hout BA, Klok RM, Brouwers JRBJ & Postma MJ (2003) A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.. Clin Ther, 25(2), 635-646.
Serruys PW, IJsselmuiden S, Hout BV, Vermeersch P, Bramucci E, Legrand V, Pieper M, Antoniucci D, Gomes RS, Macaya C , Boekstegers P et al (2003) Direct stenting with the Bx VELOCITY balloon-expandable stent mounted on the Raptor rapid exchange delivery system versus predilatation in a European randomized Trial: the VELVET trial.. Int J Cardiovasc Intervent, 5(1), 17-26.
Martin SC, Gagnon DD, Zhang L, Bokemeyer C, Van Marwijk Kooy M & van Hout B (2003) Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.. Pharmacoeconomics, 21(16), 1153-1169.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre P-F, Vincent J-L, Bernard G, van Hout B & PROWESS Investigators (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.. Crit Care Med, 31(1), 1-11.
Bonneux LGA, van Hout BA, van Delden JJM & Grobbee DE (2003) Prevention comes of age?. Eur J Epidemiol, 18(12), 1107-1108.
van Hout BA (2003) Whom and how to treat: weighing the costs and effects.. Scand J Gastroenterol Suppl(239), 3-10.
van Hout BA, Gagnon DD, McNulty P & O'Hagan A (2003) The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.. Pharmacoeconomics, 21(5), 315-326.
Van Gestel A, Bakker J, Veraart C & Van Hout B (2002) PIN1 THE COSTS OF SEVERE SEPSIS—THE NETHERLANDS, 2000. Value in Health, 5(6), 558-558.
Buskens E, Wermer M, van der Schaaf I, van Hout B, Bossuyt P & Rinkel G (2002) Screening for aneurysms after successful treatment for subarachnoid haemorrhage: Do we have the evidence?. VALUE HEALTH, 5(6), 493-494.
Fischer K, van Hout BA, van der Bom JG, Grobbee DE & van den Berg HM (2002) Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 43(5), 528-532.
Fischer K, van Hout BA, van der Bom JG, Grobbee DE & van den Berg HM (2002) Association between joint bleeds and Pettersson scores in severe haemophilia.. Acta Radiol, 43(5), 528-532.
ten Berg JM, Kelder JC, Plokker THW & van Hout BA (2002) Costs and effectiveness of using coumarins before, during and after coronary angioplasty.. Pharmacoeconomics, 20(12), 847-853.
Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E , Péchevis M et al (2002) Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.. Pharmacoeconomics, 20(1), 1-7.
Fischer K, Van Hout BA & Van den Berg M (2001) Prophylaxis or on-demand? The costs and effects of treatment strategies including switches.. BLOOD, 98(11), 428A-429A.
Gagnon DD, Martin SC & van Hout B (2001) PCN4: COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES. Value in Health, 4(2), 85-85.
Zwart-van Rijkom JE & van Hout BA (2001) Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial.. Eur Heart J, 22(16), 1476-1484.
Oostenbrink JB, Tangelder MJ, Busschbach JJ, van Hout BA, Buskens E, Algra A, Lawson JA, Eikelboom BC & Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group (2001) Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery.. J Vasc Surg, 34(2), 254-262.
Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG , Sousa JE et al (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.. Circulation, 104(5), 533-538.
van Hout BA & Simoons ML (2001) Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J, 22(9), 751-761.
Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA , Morel MA et al (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.. N Engl J Med, 344(15), 1117-1124.
Gorter JW, Oostenbrink JB, Tangelder MJD, Algra A, Buskens E, Eikelboom BC, Van Hout BA, Van Gijn J, Kappelle LJ, Koudstaal PJ , Lawson JA et al (2001) Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thrombosis and Haemostasis, 85(1), 52-56.
Moerman CJ, Van Hout BA, Bonneux L & Witteman JCM (2001) Small health benefit can be achieved with preventative postmenopausal hormone therapy in Dutch women. Nederlands Tijdschrift voor Geneeskunde, 145(19), 910-914.
Stooker T, van Acht JW, van Barneveld EM, van Vliet RC, van Hout BA, Hessing DJ & Busschbach JJ (2001) Costs in the last year of life in The Netherlands.. Inquiry, 38(1), 73-80.
Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst P, Seabra-Gomes R, Simpson I , Voudris V et al (2000) Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group.. Circulation, 102(24), 2930-2937.
Lindeboom WK, Disco CM, Unger F, Legrand V, Limet R, Van Herwerden L, Carere R, Lichtenstein S & Van Hout BA (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multivessel disease by age. CIRCULATION, 102(18), 549-549.
Lindeboom WK, Unger F, Schuler G, Mohr FW, Roose PC, Van Geldorp TR, Morel MA, Disco CM & Van Hout BA (2000) Quality of life after CABG and stented angioplasty: Results from the ARTS study. CIRCULATION, 102(18), 549-549.
Al MJ & Van Hout BA (2000) A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty.. Health Econ, 9(7), 599-609.
Lindeboom WK, van Hout BA, Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier JJRM, Schoenberger JPAM, Buller N & Bonser R (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multi vessel disease. EUR HEART J, 21, 222-222.
Moerman CJ, Van Hout BA, Bonneux L & Witteman JC (2000) Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women.. J Intern Med, 248(2), 143-150.
Brouwer W, van Hout B & Rutten F (2000) A fair approach to discounting future effects: taking a societal perspective.. J Health Serv Res Policy, 5(2), 114-118.
van Os N, Niessen LW, Bilo HJ, Casparie AF & van Hout BA (2000) Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines.. Health Policy, 51(3), 135-147.
van Buuren HR, Groeneweg M, Vleggaar FP, Lesterhuis W, van Tilburg AJP, Hop WCJ, Pieterman H, Schalm SW, van Hout BA & Lameris JS (2000) The results of a randomized controlled trial evaluating TIPS and endoscopic therapy in cirrhotic patients with gastro-esophageal variceal bleeding. J HEPATOL, 32, 71-71.
van Buuren HR, Groeneweg M, Vleggaar FP, Lesterhuis W, van Tilburg AJP, Hop WCJ, Pieterman H, Schalm SW & van Hout BA (1999) The results of a randomized controlled trial evaluating TIPS and endoscopic therapy in cirrhotic patients with gastro-esophageal variceal bleeding. European Journal of Gastroenterology & Hepatology, 11(12), A86-A86.
Serruys PW, Unger F, van Hout BA, van den Brand MJ, van Herwerden LA, van Es GA, Bonnier JJ, Simon R, Cremer J, Colombo A , Santoli C et al (1999) The ARTS study (Arterial Revascularization Therapies Study).. Semin Interv Cardiol, 4(4), 209-219.
Busschbach JJ, McDonnell J, Essink-Bot ML & van Hout BA (1999) Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D.. J Health Econ, 18(5), 551-571.
van Hout BA, Goes ES, Grijseels EW & van Ufford MA (1999) Economic evaluation in the field of cardiology: theory and practice.. Prog Cardiovasc Dis, 42(2), 167-173.
Groener MG, van Ineveld BM, Byttebier G, van Hout BA & Rutten FF (1999) An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.. Anticancer Drugs, 10(3), 283-288.
van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA & Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.. Ther Drug Monit, 21(1), 63-73.
Serruys PW, Unger F, Van Hout BA, Van den Brand MJB, Van Herwerden LA, Van Es GA, Morel MA, Bonnier JJRM, Colombo A, Morice MC , Simon R et al (1999) The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. International Journal of Cardiovascular Interventions, 2(1), 41-50.
De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A & Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study.. Osteoporos Int, 10(1), 66-72.
van Hout BA (1998) Discounting costs and effects: a reconsideration.. Health Econ, 7(7), 581-594.
Brouwer W & van Hout B (1998) How should different life expectancies be valued? Diminishing marginal utility and discounting future effects have similar consequences.. BMJ, 317(7166), 1155.
De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A & Pols HA (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam study.. J Bone Miner Res, 13(10), 1587-1593.
van Hout BA, Goes ES, Grijseels EW & Quarles van Ufford MA (1998) [Economic evaluation of cardiology; background and application].. Ned Tijdschr Geneeskd, 142(38), 2083-2086.
Casparie AF, van Hout BA & Simoons ML (1998) [Guidelines and costs].. Ned Tijdschr Geneeskd, 142(38), 2075-2077.
van Hout B (1998) Determining costs and cost-effectiveness of epilepsy.. Am J Manag Care, 4(9 Suppl), S501-S509.
Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R , Kiemeneij F et al (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet, 352(9129), 673-681.
Al MJ, van Hout BA, Michel BC & Rutten FF (1998) Sample size calculation in economic evaluations.. Health Econ, 7(4), 327-335.
van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.. Eur Heart J, 19 Suppl D, D59-D66.
van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.. Am Heart J, 135(4), S98-106.
Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D & van Hout BA (1998) Use of abciximab in interventional cardiology.. Eur Heart J, 19 Suppl D, D31-D39.
Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D & van Hout BA (1998) Use of abciximab in interventional cardiology.. Am Heart J, 135(4), S67-S76.
van Hout BA, Cohen DJ, Koens BAH & Serruys PW (1998) Costs and effects of stent implantation versus balloon angioplasty. Journal of the American College of Cardiology, 31, 50-50.
Naaborg R, Van Hout BA, Goes ES & Grijseels EWM (1998) Economic evaluation within cardiology; Background and application [4] (multiple letters). Nederlands Tijdschrift voor Geneeskunde, 142(39), 2164-2165.
Van Hout BA, Goes ES, Grijseels EWM & Quarles Van Ufford MA (1998) Economic evaluation in cardiology; background and application. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2083-2086.
Casparie AF, Van Hout BA & Simoons ML (1998) Guidelines and costs. Nederlands Tijdschrift voor Geneeskunde, 142(38), 2075-2077.
Benson T, Brouwer W & Van Hout B (1998) How should different life expectancies be valued?. BMJ, 317(7166), 1155.
Barendregt JJ, Van Oortmarssen GJ, Van Hout BA, Van Den Bosch JM & Bonneux L (1998) Coping with multiple morbidity in a life table.. Math Popul Stud, 7(1), 29-109.
van Hout BA, Simeon GP, McDonnell J & Mann JF (1997) Economic evaluation of benazepril in chronic renal insufficiency.. Kidney Int Suppl, 63, S159-S162.
van Hout B, Gagnon D, Souêtre E, Ried S, Remy C, Baker G, Genton P, Vespignani H & McNulty P (1997) Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom.. Epilepsia, 38(11), 1221-1226.
van der Riet AA, van Hout BA & Rutten FF (1997) Cost effectiveness of DNA diagnosis for four monogenic diseases.. J Med Genet, 34(9), 741-745.
De Laet CE, van Hout BA, Burger H, Hofman A & Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis.. BMJ, 315(7102), 221-225.
Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T & Vray M (1997) Modelling in economic evaluation: an unavoidable fact of life.. Health Econ, 6(3), 217-227.
Baker GA, Nashef L & van Hout BA (1997) Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality.. Epilepsia, 38 Suppl 1, S1-S8.
VandenBergh MFQ, Kluytmans JAJW, van Hout BA, Maat APWM, Seerden RJ, McDonnel J & Verbrugh HA (1996) Cost-Effectiveness of Perioperative Mupirocin Nasal Ointment in Cardiothoracic Surgery. Infection Control & Hospital Epidemiology, 17(12), 786-792.
Van Hout BA, van der Woude T, de Jaegere PP, van den Brand M, van Es GA, Serruys PW & Morel MA (1996) Cost effectiveness of stent implantation versus PTCA: the BENESTENT experience.. Semin Interv Cardiol, 1(4), 263-268.
Michel BC, van Staveren RJ, Geven WB & van Hout BA (1996) Simulation models in the planning of health care facilities: an application in the case of neonatal extracorporeal membrane oxygenation.. J Health Serv Res Policy, 1(4), 198-204.
de Laet CE, van Hout BA, Hofman A & Pols HA (1996) [Costs due to osteoporosis-induced fractures in The Netherlands; possibilities for cost control].. Ned Tijdschr Geneeskd, 140(33), 1684-1688.
Michel BC, Al MJ, Remme WJ, Kingma JH, Kragten JA, van Nieuwenhuizen R & van Hout BA (1996) Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.. Eur Heart J, 17(5), 731-740.
De Laet CEDH, Burger H, van Daele PLA, van Hout B, Hofman A & Pols HAP (1996) The cost of osteoporosis related fractures in the netherlands. Osteoporosis International, 6(S1), 124-124.
De Laet CEDH, Burger H, van Daele PLA, Pols HAP, Hofman A & van Hout B (1996) Cost-effectiveness of fracture prevention: Time of intervention. Osteoporosis International, 6(S1), 124-124.
De Laet CEDH, Van Hout BA, Hofman A & Pols HAP (1996) Costs of osteoporosis-related fractures in the Netherlands, 1993; possibilities of cost control. Nederlands Tijdschrift voor Geneeskunde, 140(33), 1684-1688.
De Boer MJ, Van Hout BA, Simoons ML & Zijlstra F (1996) Cost benefit analysis of the Zwolle Infarction Study. Hart Bulletin, 27(4), 119-123.
VandenBergh MF, Kluytmans JA, van Hout BA, Maat AP, Seerden RJ, McDonnel J & Verbrugh HA (1996) Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery.. Infect Control Hosp Epidemiol, 17(12), 786-792.
van Hout BA & Simoons ML (1995) Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands.. Eur Heart J, 16 Suppl L, 81-85.
de Boer MJ, van Hout BA, Liem AL, Suryapranata H, Hoorntje JC & Zijlstra F (1995) A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction.. Am J Cardiol, 76(11), 830-833.
van Bergen PF, Jonker JJ, van Hout BA, van Domburg RT, Deckers JW, Azar AJ & Hofman A (1995) Costs and effects of long-term oral anticoagulant treatment after myocardial infarction.. JAMA, 273(12), 925-928.
Michel BC & van Hout BA (1994) [Is the use of helicopters with a trauma team in severely injured accident victims in The Netherlands cost effective? A modelling approach].. Ned Tijdschr Geneeskd, 138(46), 2310-2315.
Michel BC, Van Hout BA & Bonsel GJ (1994) Assessing the benefits of transplant services.. Baillieres Clin Gastroenterol, 8(3), 411-423.
van Hout BA, Al MJ, Gordon GS & Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial.. Health Econ, 3(5), 309-319.
Rutten FFH & Van Hout BA (1994) Economic evaluation and the reimbursement of drugs: Current policies and future trends. European Journal of Clinical Research, 6, 186-194.
Michel BC & Van Hout BA (1994) Is use of helicopters with medical crews for seriously injured accident victims cost-effective in the Netherlands? A modelling approach. Nederlands Tijdschrift voor Geneeskunde, 138(46), 2310-2315.
van Hout BA, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM & Rutten FF (1994) Cost-effectiveness of HA-1A treatment for patients with sepsis.. Prog Clin Biol Res, 388, 435-443.
van Hout BA, Wielink G, Bonsel GJ & Rutten FF (1993) Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.. Pharmacoeconomics, 3(5), 387-397.
van Hout B, Bonsel G, Habbema D, van der Maas P & de Charro F (1993) Heart transplantation in the Netherlands; costs, effects and scenarios.. J Health Econ, 12(1), 73-93.
Van Hout BA, Rutten FF & Lorijn RH (1993) [Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome].. Ned Tijdschr Geneeskd, 137(7), 360-364.
Van Hout BA, Rutten FFH & Lorijn RHW (1993) Cost-effectiveness of treatment of patients with sepsis with HA-IA. Nederlands Tijdschrift voor Geneeskunde, 137(7), 360-364.
BUXTON M, OHANLON M, RUSHBY J, PEKURINEN M, SINTONEN H, BONSEL G, ESSINKBOT ML, VANHOUT B, BJORK S, LINDGREN B , PERSSON U et al (1992) EUROQOL(C) - A REPLY AND REMINDER. HEALTH POLICY, 20(3), 329-332.
Monreal M, Agnelli G, Chuang LH, Cohen AT, Gumbs PD, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Willich SN & Van Hout B () Deep vein thrombosis in Europe—health-related quality of life and mortality. Clinical and Applied Thrombosis/Hemostasis, 25. View this article in WRRO

Chapters

Oppe M, Norman R, Yang Z & van Hout B (2022) Experimental Design for the Valuation of the EQ-5D-5L, Value Sets for EQ-5D-5L (pp. 29-54). Springer International Publishing
van Hout B & McDonnell J (2005) Estimating a parametric relation between health description and health valuation using the EuroQol Instrument, EQ-5D concepts and methods: A developmental history (pp. 157-170). Springer Netherlands
de Charro F, Busschbach J, Essink-Bot M-L, van Hout B & Krabbe P (2005) Some considerations concerning negative values for EQ-5D health states, EQ-5D concepts and methods: A developmental history (pp. 171-179). Springer Netherlands
van Hout BA & Angus DC (2003) How should we Measure the Economic Consequences of Critical Illness?, Surviving Intensive Care (pp. 221-234). Springer Berlin Heidelberg

Conference proceedings papers

Verburg-Baltussen L, Dunnewind N, Kroep S, Hout BV, Boing E & Keen R (2023) RELATIONSHIPS BETWEEN HETEROTOPIC OSSIFICATION VOLUME AND FUNCTIONAL AND QUALITY OF LIFE ENDPOINTS IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S28-S29)
Shaw J, Bennett B, Russell J, Van HBA, Norman R, Frampton K, Moreno-Koehler A, Taylor F & Cocks K (2023) THE IMPACTS OF AGE AND GENDER ON MAPPED EQ-5D5L UTILITIES AND QUALITY-ADJUSTED LIFE YEARS (QALYS) IN CANCER CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(6) (pp S334-S334)
Shaw J, Bennett B, Khan I, Van Hout BA, Bryning S, Fox A & Hirst A (2023) COMPARING ALGORITHMS FOR MAPPING FROM EQ-5D-3L TO EQ-5D-5L IN TWO PATIENT COHORTS. VALUE IN HEALTH, Vol. 26(6) (pp S343-S344)
Verburg-Baltussen L, Gittfried A, Kroep S, Hout BV, Boing E & Keen R (2023) RELATING HETEROTOPIC OSSIFICATION VOLUME TO JOINT FUNCTION AND QUALITY OF LIFE: A SIMULATION STUDY IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP). VALUE IN HEALTH, Vol. 26(6) (pp S288-S288)
Malottki K, Lawson R, Beecroft S, Van Hout BA, Heaton D, Starita C & Patel S (2022) RWD5 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Pompe Disease in England. Value in Health, Vol. 25(12) (pp S448-S448)
Durno N, Heisen M, Penton H, Schmid R, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San José Cáceres A , Mühlbacher AC et al (2022) PCR279 Value-Based Assessment of Clinical Trial Outcomes: A Hypothetical Example Using the Childhood Autism Rating Scale in Autism Spectrum Disorder. Value in Health, Vol. 25(12) (pp S444-S444)
Schneider P, Brazier JE, Van Hout BA & Devlin N (2022) PCR166 Online Elicitation of Personal Utility Functions (OPUF) – An Open, Modular Health Valuation Platform. Value in Health, Vol. 25(12) (pp S423-S423)
Schneider P, Brazier JE, Devlin N & van Hout B (2022) PCR28 The OPUF Tool: A New Type of Online Survey for Creating Value Sets for the EQ-5D-5L on the Societal-, Group-, and Individual Person Level. Value in Health, Vol. 25(7) (pp S546-S546)
Schneider P, Brazier J, Devlin N & Hout BV (2022) 85:oral The EQ-5D-5L OPUF survey: quantifying health priorities on the individual person level using compositional preference elicitation techniques. Abstracts
Schneider P, Brazier JE, Devlin N & van Hout B (2022) THE OPUF TOOL: A NEW TYPE OF ONLINE SURVEY FOR CREATING VALUE SETS FOR THE EQ-5D-5L ON THE SOCIETAL-, GROUP-, AND INDIVIDUAL PERSON LEVEL. VALUE IN HEALTH, Vol. 25(7) (pp S546-S546)
Schneider P, Van Hout B, Heisen M, Brazier J & Devlin N (2022) A NEW ONLINE TOOL FOR VALUING HEALTH STATES: ELICITING PERSONAL UTILITY FUNCTIONS FOR THE EQ-5D-5L. VALUE IN HEALTH, Vol. 25(1) (pp S13-S13)
Schneider P, Brazier J, van Hout B & Devlin N (2022) Online Elicitation of Personal Utility Functions (OPUF): An Open, Modular Health Valuation Platform. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, Vol. 15(6) (pp 734-734)
Schneider P, Brazier J, van Hout B & Devlin N (2022) The Online elicitation of Personal Utility Functions (OPUF) Tool: a new method to construct (patient) preferences for small groups and on the individual level. QUALITY OF LIFE RESEARCH, Vol. 31 (pp S9-S10)
Schneider P, Brazier JE, Van Hout BA & Devlin N (2022) ONLINE ELICITATION OF PERSONAL UTILITY FUNCTIONS (OPUF) AN OPEN, MODULAR HEALTH VALUATION PLATFORM. VALUE IN HEALTH, Vol. 25(12) (pp S423-S423)
Durno N, Heisen M, Penton H, Schmid R, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muhlbacher AC et al (2022) VALUE-BASED ASSESSMENT OF CLINICAL TRIAL OUTCOMES: A HYPOTHETICAL EXAMPLE USING THE CHILDHOOD AUTISM RATING SCALE IN AUTISM SPECTRUM DISORDER. VALUE IN HEALTH, Vol. 25(12) (pp S444-S444)
Malottki K, Lawson R, Beecroft S, Van Hout BA, Heaton D, Starita C & Patel S (2022) USING LINKED DATABASES TO EXPLORE RESOURCE USE AND REAL-WORLD OUTCOMES IN A RARE DISEASE: POMPE DISEASE IN ENGLAND. VALUE IN HEALTH, Vol. 25(12) (pp S448-S448)
Hartl K, Durno N, Schmid R, Heisen M, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, San Jose Caceres A , Muehlbacher A et al (2021) Preference Study in Childhood Autism Spectrum Disorder (ASD) using the Childhood Autism Rating Scale (CARS2): A Feasibility Assessment. QUALITY OF LIFE RESEARCH, Vol. 30(SUPPL 1) (pp S113-S114)
Schneider P, Van Hout B & Brazier J (2020) FAIR INTERPERSONAL UTILITY COMPARISON IN THE CONTEXT OF HEALTH VALUATION: DESCRIPTION AND FIRST EMPIRICAL EVALUATION OF A NEW MULTI-STEP PREFERENCE AGGREGATION PROCEDURE. MEDICAL DECISION MAKING, Vol. 40(5) (pp E407-E408)
Morrone D, Ricci F, Giulia R, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2020) Additive predictive power of the cha2ds2-vasc and has-bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 22(N) (pp N10-N10)
Lindgren P, Hagström E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) PCV40 COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. Value in Health, Vol. 22 (pp S548-S548)
Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Eriksson Svensson M & Fonarow GC (2019) P1225Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. European Heart Journal, Vol. 40(Supplement_1)
Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) P654Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. European Heart Journal, Vol. 40(Supplement_1)
Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) TWO-YEAR SURVIVAL WITH AXICABTAGENE CILOLEUCEL IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: AN UPDATED ANALYSIS. HemaSphere, Vol. 3 (pp 817-817)
Fonarow GC, van Hout B, Villa G, Arellano J & Lindgren P (2019) An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline. Journal of Clinical Lipidology, Vol. 13(3) (pp e31-e31)
Diakite I, Lin VW, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M & van Hout B (2019) MS2 AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL). Value in Health, Vol. 22 (pp S41-S41)
Morrone D, Ricci F, Renda G, Patti G, Kirchhof P, Kroep S, Chuang L-H, Van Hout B & De Caterina R (2019) Additive predictive power of the CHA2DS2-VASc and has bled scores for mortality in patients with atrial fibrillation. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 21(J) (pp J23-J23)
Ray KK, Schoonen M, Annemans L, Van Hout BA, Sibartie M, Bridges I & Bruckert E (2019) Effectiveness of evolocumab for patients with familial hypercholesteraemia (FH) in European clinical practice. EUROPEAN HEART JOURNAL, Vol. 40 (pp 263-263)
Lindgren P, Hagstrom E, Van Hout B, Villa G, Urbich M, Sandelin R, Svensson ME & Fonarow GC (2019) Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden. EUROPEAN HEART JOURNAL, Vol. 40 (pp 681-681)
Lindgren P, Hagstrom E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Sibartie M & Fonarow GC (2019) COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN. VALUE IN HEALTH, Vol. 22 (pp S548-S548)
Ray K, Bruckert E, Annemans L, Van Hout B, Schoonen M & Bridges I (2018) P1699Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines?. European Heart Journal, Vol. 39(suppl_1)
Kroep S, Chuang L-H, Cohen A, Gumbs P, van Hout B, Monreal M, Willich SN, Gitt A, Bauersachs R & Agnelli G (2018) The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, Vol. 46(4) (pp 507-515)
Kroep S, Chuang L, van Hout B, Agnelli G, Gumbs PD, Gitt AK, Monreal M, Bauersachs R, Mismetti P, Willich SN & Cohen AT (2017) The Impact Of Co-Morbidity On The Disease Burden Of VTE. Value in Health, Vol. 20(9) (pp A601-A601)
Chuang L, Cohen AT, Agnelli G, Gumbs PD, Bauersachs R, Kroep S, Mismetti P, Gitt AK, Monreal M, Willich SN & van Hout B (2017) The Comparison of EQ-5D-5L Versus Disease/Treatment-Specific Measures in Pulmonary Embolism and Deep Vein Thrombosis. Value in Health, Vol. 20(9) (pp A623-A623)
Chuang L, van Hout B, Cohen AT, Gumbs PD, Kroep S, Monreal M, Willich SN & Agnelli G (2017) Burden Of Illness Of Deep-Vein Thrombosis In Europe – Healthcare Resource Utilization And Productivity Loss. Value in Health, Vol. 20(9) (pp A612-A612)
Danese M, Villa G, Taylor B, Lindgren P, Van Hout B & Lothgren M (2017) OBSERVED VERSUS PREDICTED CARDIOVASCULAR EVENT RATES IN PRIMARY PREVENTION DIABETIC PATIENTS RECEIVING HIGH-INTENSITY STATINS IN THE UNITED KINGDOM. Journal of the American College of Cardiology, Vol. 69(11) (pp 1852-1852)
Monreal M, Agnelli G, Chuang L, Cohen AT, Gumbs PD, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Willich SN & van Hout B (2017) BURDEN OF ILLNESS OF DEEP VEIN THROMBOSIS IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
Chuang L, Gumbs PD, van Hout B, Agnelli G, Cohen AT, Bauersachs R, Mismetti P, Gitt AK, Kroep S, Monreal M , Willich SN et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - MORTALITY AND HEALTH RELATED QUALITY OF LIFE. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
Willich SN, Chuang L, van Hout B, Agnelli G, Gumbs PD, Bauersachs R, Mismetti P, Jimenez D, Gitt AK, Kroep S , Monreal M et al (2017) BURDEN OF ILLNESS OF PULMONARY EMBOLISM IN EUROPE - HEALTHCARE RESOURCE UTILIZATION AND PRODUCTIVITY LOSS. VALUE IN HEALTH, Vol. 20(9) (pp A611-A611)
Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, Sorio F, Masana L, Bayes-Genis A & van Hout B (2016) Cost-Effectiveness of Evolocumab in Patients with High Cardiovascular Risk in Spain. Value in Health, Vol. 19(7) (pp A651-A652)
Gumbs PD, Ling-Hsiang Chuang L, Cohen AT, Agnelli G, Willich SN, Monreal M, Jimenez D & van Hout B (2016) The Economic Burden of Pulmonary Embolism in Europe. Value in Health, Vol. 19(7) (pp A365-A365)
Clay E, Jamotte A, Cohen AT, van Hout B, Gumbs PD & Verhamme P (2016) Cost-Effectiveness of Edoxaban Compared to Warfarin for The Treatment and Secondary Prevention of Venous Thromboembolism in The UK. Value in Health, Vol. 19(7) (pp A653-A654)
van Hout B, Gumbs PD, Cohen AT & Verhamme P (2016) An Analysis of the Efficacy and Safety of Edoxaban in Comparison with Rivaroxaban in the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Value in Health, Vol. 19(7) (pp A637-A638)
Pantiri K, Shah K, Devlin N, Mulhern B & van Hout B (2016) Directly Eliciting Personal Utility Functions From A Convenience Sample Of 30 Health Outcomes Professionals: A Pilot Study. Value in Health, Vol. 19(7) (pp A473-A473)
Stapelkamp C, Byrne B & van Hout B (2016) Adjustment Of OS In Crystal For Post-Study Anti-Cancer Therapies. Value in Health, Vol. 19(7) (pp A394-A394)
Gandra SR, Villa G, Fonarow G, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab In Patients With High Cardiovascular Risk In The United States. Value in Health, Vol. 19(3) (pp A3-A3)
Shah K, Devlin N, Mulhern B & van Hout B (2015) Directly Eliciting Personal Utility Functions: A New Way To Value Health-Related Quality Of Life. Value in Health, Vol. 18(3) (pp A37-A37)
Villa G, Lothgren M, Gandra SR, Lindgren P & van Hout B (2014) Deterministic Versus Stochastic Prediction of Risk for Cardiovascular Events. Value in Health, Vol. 17(7) (pp A558-A558)
Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2014) 129 Cost effectiveness of XPS vs TURP, a UK analysis. European Urology Supplements, Vol. 13(1) (pp e129-e129)
Begum N, Van Hout B, Thurston S, Schoeman O, Fraschke A & Verheugt FWA (2013) Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden. Value in Health, Vol. 16(7) (pp A524-A524)
Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2013) MULTINATIONAL CONSISTENCY OF A DISCRETE CHOICE MODEL IN QUANTIFYING HEALTH STATES FOR THE EXTENDED 5-LEVEL EQ-5D. VALUE IN HEALTH, Vol. 16(7) (pp A326-A326)
Chuang LH, Treur M, Heeg B, Van Hout B & Filonenko A (2013) The use and impact of value of information analysis in decision-making.. Value Health, Vol. 16(3) (pp A30). United States
Solem CT, Niederman MS, Chastre J, Wan Y, Gao X, Myers DE, Haider S, Chambers R, Li JZ, Van Hout BA & Stephens JM (2012) HEALTH CARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS TREATED FOR NOSOCOMIAL PNEUMONIA (NP) CAUSED BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA): SECONDARY ANALYSIS OF A MULTI-CENTER RANDOMIZED CONTROLLED STUDY. VALUE IN HEALTH, Vol. 15(4) (pp A10-A10)
Van Hout BA & Oppe M (2011) COMBINING DCE AND TTO INTO A SINGLE VALUE FUNCTION. VALUE IN HEALTH, Vol. 14(7) (pp A238-A239)
Van Hout BA & Stevens JW (2011) THE POWER OF ASSUMPTIONS. VALUE IN HEALTH, Vol. 14(7) (pp A235-A235)
Treur M, Houwing NS, Heeg B, Kristanto P, Botteman M, Vo P, Marx S, Lockhart E & Van Hout B (2010) A CONCEPTUAL FRAMEWORK THAT CAPTURES THE MULTIDIMENSIONAL ASPECT OF ADHERENCE IN A HEALTH-ECONOMIC MODEL: AN APPLICATION IN CHRONIC NONMALIGNANT PAIN MANAGEMENT. VALUE HEALTH, Vol. 13(7) (pp A242-A243)
Thurston S, Webb C, Borgman B & Van Hout B (2010) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN SWEDEN. VALUE IN HEALTH, Vol. 13(3) (pp A166-A167)
Thurston S, Webb C, Rejas J & Van Hout B (2010) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME (ACS) PATIENTS IN SPAIN. VALUE HEALTH, Vol. 13(3) (pp A165-A166)
Van Hout BA, Botteman M & Dukler A (2010) THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN MULTIPLE SCLEROSIS (MS). VALUE HEALTH, Vol. 13(3) (pp A137-A137)
Gu NY, Bell C, Botteman M & Van Hout BA (2010) COMPARING THE TIME TRADEOFF (TTO), THE VISUAL ANALOGUE SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A212-A212)
Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSOCIATION BETWEEN SELF-REPORTED NEUROPATHIC PAIN SEVERITY AND THE EQ-5D IN PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN). VALUE HEALTH, Vol. 13(3) (pp A213-A213)
Gu NY, Bell C, Botteman M & Van Hout BA (2010) ASSESSING THE IMPACT OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA (PHN) RELATED HEALTH IMPAIRMENT ON LOSS OF PRODUCTIVE TIME (LOPT). VALUE HEALTH, Vol. 13(3) (pp A61-A61)
Bojke C, Cifaldi M, Ray S & Van Hout B (2010) MAINTENANCE OF PHYSICAL FUNCTION IMPROVES EMPLOYMENT STATUS OVER TIME FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 49 (pp I72-I73)
Logman F, Heeg B, Botteman M, Kaura S & van Hout B (2009) Economic Evaluation of Zoledronic Acid for the Prevention of Osteoporotic Fractures in Post-Menopausal Women with Early Breast Cancer Receiving Aromatase Inhibitors in the United Kingdom. CANCER RESEARCH, Vol. 69(24) (pp 574S-574S)
Thurston SJ, Webb K, Ong S, Meerding WJ & van Hout BA (2009) COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS. VALUE HEALTH, Vol. 12(7) (pp A335-A335)
Heeg BMS, Treur MJ & van Hout BA (2009) HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
On MMLL, Heeg BMS, De Charro F & van Hout BA (2009) COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS. VALUE HEALTH, Vol. 12(7) (pp A235-A235)
van Hout BA (2009) THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE. VALUE HEALTH, Vol. 12(3) (pp A4-A5)
van Hout BA (2009) THE POWER OF ASSUMPTIONS. VALUE HEALTH, Vol. 12(3) (pp A34-A34)
Leen C, Thuresson PO, Hegg B, Vardeva K, Gosden T, Yogaratnam JZ & Van Hout B (2009) Cost-effectiveness of atazanavir compared to lopinavir in treatment-naive HIV-1 patients in Scotland. HIV MED, Vol. 10 (pp 41-42)
Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens JM, Haider S, Cappelleri JC, Nathwani D, Tice A & Van Hout BA (2008) ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS. VALUE HEALTH, Vol. 11(6) (pp A428-A428)
Verheggen BG, Heeg BMS, Vos CBJ & Van Hout BA (2008) COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS. VALUE HEALTH, Vol. 11(6) (pp A437-A437)
Verheggen BG, Treur MJ, Heeg BMS, Botteman MF, Van Hout BA & Trocio JN (2008) ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER. VALUE HEALTH, Vol. 11(6) (pp A655-A655)
Thuresson PO, Heeg B, Neubauer AS, Intorcia M & Van Hout BA (2008) COST EFFECTIVENESS ANALYSIS OF REYATAZ (R) VERSUS KALETRA (R) IN THE TREATMENT OF NAIVE HIV PATIENTS IN ITALY. VALUE HEALTH, Vol. 11(6) (pp A351-A351)
Thurston SJ, Thompson RP, Ong S & van Hout BA (2008) COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK. VALUE HEALTH, Vol. 11(6) (pp A405-A405)
Logman JFS, Treur MJ, Verheggen BG, Heeg BMS, Stephens J, Spiesser J, Simoneau D, Haider S, Nathwani D & Van Hout BA (2008) A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS). VALUE HEALTH, Vol. 11(6) (pp A428-A428)
Treur MJ, Heeg B, Moller HJ, Schmeding A & Van Hout BA (2008) A pharmacoeconomic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss. VALUE HEALTH, Vol. 11(3) (pp A118-A118)
Treur MJ, McCracken F, Heeg B, Joshi AV, Thurston S, Verbeggen B, Marc B, de Charro F & van Hout B (2007) Efficacy of recombinant activated factor VII (rFVlla) vs. activated prothrombin complex concentrate (APCC) in patients with hemophilia with inhibitors: A Bayesian meta-analysis. BLOOD, Vol. 110(11) (pp 59B-59B)
Van der Steen A, Verheggen BG, Heeg BMS & Van Hout BA (2007) Dealing with competing causes of death, illness and costs: The Disease Elimination Life Table Analysis (DELTA) model. VALUE HEALTH, Vol. 10(6) (pp A454-A454)
Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) A pharmacoeconomic analysis of compliance gains on antipsychotic medications. VALUE HEALTH, Vol. 10(6) (pp A294-A294)
Damen J, Heeg B, Lothgren M & Van Hout BA (2007) The cost effectiveness of paliperidone extended-release OROS in Sweden, Finland, Denmark and Norway. VALUE HEALTH, Vol. 10(6) (pp A294-A295)
Van der Steen A, Heeg B, De Charro F & Van Hout BA (2007) Spatial interpolation. VALUE HEALTH, Vol. 10(6) (pp A453-A453)
Treur MJ, McCraken F, Heeg BMS, Joshi AV, Botteman MF, De Charro F & Van Hout BA (2007) Recombinant activated factor VII (RFVIIA)vs. activated prothrombin complex concentrate (APCC) for on-demand treatment of joint bleeds in hemophiliacs with inhibitors: A systematic review and Bayesian meta-regression survival model with time-dependent covariates. VALUE HEALTH, Vol. 10(6) (pp A284-A285)
Damen J, Heeg BMS, Lothgren M & Van Hout BA (2007) The cost-effectiveness of risperidone long-acting injectable in Sweden. VALUE HEALTH, Vol. 10(6) (pp A293-A294)
Borkent-Raven BA, Janssen MP, De Wit A, Koedijk FD, Van Hout BA & Van der Poel CL (2007) Costs and effects of HBV-NAT screening in the Netherlands. TRANSFUSION, Vol. 47(3) (pp 266A-266A)
Borkent-Raven BA, Janssen MP, Van Hout BA & Van der Poel CL (2007) The fate of blood components: Distributions of patients to whom they are transfused, their age and diagnoses. TRANSFUSION, Vol. 47(3) (pp 268A-269A)
Logman F, Heeg B, Botteman MF, Marfatia AA & Van Hout BA (2007) Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom. EJC SUPPLEMENTS, Vol. 5(4) (pp 156-156)
Janssen MP, Van der Poel CL, Schaasberg WP, Bonsel GJ & Van Hout BA (2006) Ten years of blood transfusions: Use, disease and survival. TRANSFUSION, Vol. 46(9) (pp 153A-154A)
Janssen MP, van der Poel CI, Schaasberg W, Bonsel GJ & Van Hout BA (2006) Ten years of blood transufsions: Use, disease and survival. VOX SANG, Vol. 91 (pp 319-319)
Botteman MF, Hay JW, Van Hout BA, Curry A, Wong R & Luo MP (2006) Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS). ANNALS OF THE RHEUMATIC DISEASES, Vol. 65 (pp 207-208)
Klok RM, Postma MJ, Van Hout BA & Brouwers JR (2005) All proton pump inhibitors are equivalent for treatment of GERD. CLEV CLIN J MED, Vol. 72(12) (pp 1100-1100)
Van Hout B (2005) Cost effectiveness of fondaparinux compared with enoxaparin for extended prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery using Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
Van Hout B (2005) Cost effectiveness of extended prophylaxis with fondaparinux to prevent venous thromboembolism in patients undergoing hip fracture surgery using UK and Dutch estimates of costs. VALUE HEALTH, Vol. 8(6) (pp A116-A116)
Heeg B, Buskens E, Ingham M, Caleo S, Rabinowitz J & Van Hout B (2005) A discrete event simulation (DES) model to describe schizophrenia. VALUE HEALTH, Vol. 8(6) (pp A207-A207)
Cohen DJ, Dulisse B, Ryan JW, de Bruyne B, Van Hout BA & Serruys PW (2005) Cost-effectiveness of PCI with or without drug-eluting stents vs. bypass surgery for treatment of multivessel coronary disease: 1-year results from the ARTS I and ARTS II trials. CIRCULATION, Vol. 112(17) (pp U612-U612)
Heeg BM, Buskens E, Serra AV, Palha AP, Teixeira JM, Figueira L, Jara J & van Hout B (2004) Costs and effects of Risperdal Consta (TM) in comparison to conventional depot and shortacting atypical formulations in Portugal. VALUE HEALTH, Vol. 7(6) (pp 778-778)
Heeg BMS, Buskens E & van Hout BA (2004) The costs and effects of clopidogrel in comparison to ASA or placebo for several patient populations in Denmark. VALUE HEALTH, Vol. 7(6) (pp 642-642)
Verschuuren M, van Hout BA & Bonsel GJ (2004) VIOLATIONS OF THE ADDITIVE ASSUMPTION IN THE STANDARD QALY APPROACH: EXTRA-MAXIMAL TRADE OFFS. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1570-1570)
Verschuuren M, van Hout BA & Bonsel GJ (2004) MODELING TIME TRADE OFF VALUATIONS: IN SEARCH OF A GOOD FIT. QUALITY OF LIFE RESEARCH, Vol. 13(9) (pp 1499-1499)
Heeg BM, Emmermann A, Laux G, Moller HJ, Naber D & Van Hout BA (2003) Costs and effects of risperdal Consta (TM) in comparison to conventional depot and short-acting atypical formulations in Germany. VALUE HEALTH, Vol. 6(6) (pp 692-692)
van Hout BA, Tangelder MJD, Bervoets P & Gabriel S (2003) Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation in the Netherlands. VALUE HEALTH, Vol. 6(6) (pp 667-668)
Azar A, Hoes A, Arends L, Van den Voorde-Rosenbrand K, Bots M, van Hout B, Lubsen J & Grobbee D (2003) Efficacy of treatment of hypertension: A meta-analysis of 68,000 patients and its implications for current practice. JOURNAL OF HYPERTENSION, Vol. 21 (pp S115-S115)
Lamfers EJ, Schut A, Hooghoudt TE, Hertzberger DP, Stolwijk PW, Boersma E, Verheugt FWA & Van Hout BA (2003) Cost-effectiveness of prehospital thrombolysis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 41(6) (pp 524A-524A)
Van Gestel A, Bakker J, Van Hout B & Veraart C (2002) The costs of severe sepsis - The Netherlands, 2000. VALUE HEALTH, Vol. 5(6) (pp 561-561)
Van Gestel A, Bakker J, Veraart C & Van Hout B (2002) Incidence of severe sepsis in the Netherlands: A point prevalence survey. VALUE HEALTH, Vol. 5(6) (pp 576-576)
Heeg BM, van Aalst G, van den Arend IJ, Mehnert A & van Hout B (2002) A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia. VALUE HEALTH, Vol. 5(6) (pp 515-516)
Heeg BM, van Aalst GD, Mehnert A & van Hout B (2002) Simulating the course of schizophrenia using discrete events modelling. VALUE HEALTH, Vol. 5(6) (pp 524-524)
Lindeboom WK, van Hout BA, Serruys PWS, Unger F, Taeymans Y, van Nooten G, Pieper M & Maass D (2002) Working status after CABG and stented angioplasty: results from the ARTS study. EUROPEAN HEART JOURNAL, Vol. 23 (pp 260-260)
van Hout BA, Lindeboom WK, Morice MC, de Jong P, Molnar F, Wijns W, Holubarsch C, Bartorelli A & RAVEL investigators (2002) Cost-effectiveness of the sirolimus eluting Bx-VELOCITY stent: 1-year results. EUROPEAN HEART JOURNAL, Vol. 23 (pp 691-691)
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard GR, van Hout B & PROWESS Investigators (2002) Cost-effectiveness of drotrecogin alfa (activated) (Xigris (TM)) in severe sepsis. CRIT CARE MED, Vol. 30(2) (pp 493-493)
Linde-Zwirble WT, Clermont G, Van Hout B, Ball DE, Basson BR & Angus DC (2001) Increased survivorship with drotrecogin alfa (activated) in the treatment of severe sepsis: The effect on hospital costs. CRIT CARE MED, Vol. 29(12) (pp A1-A1)
Abizaid A, Costa M, Centemero M, Abizaid A, Legrand VMG, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AGMR , Sousa JE et al (2001) Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: Insights from the arterial revascularization therapy study (ARTS) trial.. AM J CARDIOL, Vol. 88(5A) (pp 4G-4G)
Sheiban I (2001) Stenting is less expensive than bypass surgery for multivessel coronary disease but is associated with repeat revascularization. Evidence-based Cardiovascular Medicine, Vol. 5(3) (pp 94-95)
Lindeboom WK, Van Hout BA, Backx B, Unger F, Sousa JE, Jatene A, Bonnier JJRM, Schoenberger JPAM, Buller N & Bonser R (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in diabetic patients with multivessel disease. CIRCULATION, Vol. 102(18) (pp 550-550)
Disco CMC, Lindeboom WK, Serruys PW, Unger F, Legrand V, Limet R, van Herwerden L, Carere R, Lichtenstein S & van Hout BA (2000) Comparison of effectiveness and cost effectiveness of CABG versus percutaneous intervention in patients with multi-vessel disease assessed by age. EUR HEART J, Vol. 21 (pp 478-478)
Lindeboom WK, Serruys PW, Unger F, Schuler G, Mohr FW, Roose PCH, van Geldrop THR, Morel MAM, Disco CMC & van Hout BA (2000) Quality of life after CABG and stented angioplasty: results from the ARTS study. EUR HEART J, Vol. 21 (pp 221-221)
De Bruyne B, Serruys PW, Carlier S, van Hout B, van Sonsbeek JM, Gurne O, Pijls NHJ, Ziekenhuis C, Belardl JA, Germonprez JL , Schofield PM et al (1999) Debate II: A randomized comparison of cost-effectiveness of primary versus provisional stenting. CIRCULATION, Vol. 100(18) (pp 790-791)
Van Os N, Niessen LW, Casparie AF & Van Hout BA (1999) Cost-effectiveness analysis of national clinical guidelines. DIABETES, Vol. 48 (pp A416-A416)
Serruys PW, Unger F, van Herwerden L, Mohr F, Simon R, Albrechts C, Wijns W, van Hout B, van Es GA, Hugenholtz PG & Morel MA (1998) Arterial revascularisation therapy study: The ARTS study, a randomised trial of bypass-surgery versus stenting in multivessel coronary disease.. CIRCULATION, Vol. 98(17) (pp 498-498)
Heeschen C, Hamm CW, Goldmann BU, Wohlrath S, van Hout BA & Simoons ML (1998) Cost effectiveness of abciximab in patients with unstable angina according to the troponin T status. CIRCULATION, Vol. 98(17) (pp 358-359)
van Hout B, Gagnon D & McNulty P (1998) Assessing the probability of economic dominance without data from a head to head trial. MED DECIS MAKING, Vol. 18(4) (pp 489-489)
van Hout BA, Bowman L, Zelinger DJ & Simoons ML (1998) Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. EUROPEAN HEART JOURNAL, Vol. 19 (pp D59-D66)
van Hout BA, Cohen DJ, Koens BAH & Serruys PW (1998) Costs and effects of stent implantation versus balloon angioplasty. J AM COLL CARDIOL, Vol. 31(2) (pp 50A-50A)
DeLaet CEDH, vanHout B, Burger H, Hofman A & Pols HAP (1997) Cost-effectiveness of hip fracture prevention: The later the better?. J BONE MINER RES, Vol. 12 (pp F558-F558)

Reports

Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2016) Valuing health-related quality of life: An EQ-5D-5L value set for England
Ara R, Kearns B, Mukuria C, van Hout B & Brazier JE (2013) Examining productivity losses associated with health related quality of life using patient and general population data. View this article in WRRO
ara R, van hout B, Kearns B & Brazier JE (2013) Case-mix methodology for the NHS outcomes framework GP Patient Survey Questionnaire Data View this article in WRRO

Posters

Schneider P, van Hout B, Heisen M, Brazier JE & Devlin N (2022) P60 A New Online Tool for Valuing Health States: Eliciting Personal Utility Functions for the EQ-5D-5L.

Working papers

Devlin NJ, Shah KK, Feng Y, Mulhern B & van Hout B (2018) Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United Kingdom), 27, 7-22. View this article in WRRO

Other

Piena MA, Kroep S, Simons C, Fenwick E, Harty GT, Wong SL & van Hout BA (2022) Correction to: An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach. Advances in Therapy, 39(2), 909-909.

Preprints

Durno N, Zormpas E, Schmid R, Heisen M, Hartl K, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T , Cáceres ASJ et al () Health Preferences in Childhood Autism Spectrum Disorder (ASD): A Discrete Choice Experiment using the Childhood Autism Rating Scale (CARS2), Research Square Platform LLC.
Hartl K, Durno N, Schmid R, Heisen M, Ethgen O, Szilvasy Z, Friedel E, Wong O, Charman T, Cáceres ASJ , Mühlbacher A et al () Feasibility Assessment of a Health Preference Study in Autism Based on the Childhood Autism Rating Scale (CARS2): A Qualitative Study with Clinicians and Caregivers, Research Square Platform LLC.
Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling CJ, Wilkinson G & van Hout B () A Comparison of Alternative Variants of the Lead and Lag Time TTO.

School of Medicine and Population Health

School of Medicine and Population Health

Professor Ben van Hout

Featured publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

Reports

Posters

Working papers

Other

Preprints

Links